Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: A systematic review and meta-analysis

Wonyoung Cho, Sangil Park, Hyeon Jin Kim, Myeongcheol Lee, Yong Sung Choi, Seung Geun Yeo, Jinseok Lee, Ai Koyanagi, Louis Jacob, Lee Smith, Masoud Rahmati, Suhana Ahmad, Guillaume Fond, Laurent Boyer, Sang Youl Rhee, Seung Won Lee, Jae Il Shin, Ho Geol Woo, Dong Keon Yon

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)

Abstract

On 23 July 2022, the World Health Organization declared the global mpox outbreak as a public health emergency of international significance. The mpox virus (MPXV) that caused the outbreak was classified as clade IIb, which belongs to the West African clade. However, the relationship between MPXV clades and symptoms, as well as the severity of mpox outcomes, is not fully understood. Thus, we aimed to investigate the global mpox prevalence and the differences in clinical manifestations and outcomes among patients with mpox between pre-outbreak (2003–2021) and the current mpox outbreak. In this systematic review and meta-analysis, PubMed/MEDLINE, Web of Science, Embase, Cumulative Index to Nursing and Allied Health Literature, and Google Scholar were searched using the keyword “monkeypox” and “mpox” up to 13 October 2022. A random effects model was used to obtain the pooled prevalence and 95% confidence intervals. This study included 27 articles, and 5698 patients with mpox with 19 distinctive features from 19 countries across five continents were assessed. Patients with mpox during the 2022 mpox outbreak showed mild clinical manifestations and outcomes compared with those before the 2022 mpox outbreak: mild rash (relative ratio [RR]: 5.09, 95% confidence interval [CI]: 1.52–17.08), fever (0.68, 0.49–0.94), pruritus (0.25, 0.19–0.32), myalgia (0.50, 0.31–0.81), headache (0.56, 0.35–0.88), skin ulcer (0.32, 0.17–0.59), abdominal symptom (0.29, 0.20–0.42), pharyngitis (0.32, 0.18–0.58), nausea or vomiting (0.15, 0.02–0.93), conjunctivitis (0.11, 0.03–0.38), concomitant infection with HIV (1.70, 0.95–3 0.04), and death (0.02, 0.001–0.31). MPXV clade IIb exhibited higher infectivity but may cause mild disease symptoms and low mortality rate. It is important to consider MPXV infection in patients with mpox-related features and/or a history of sexual transmission to prevent the spread of the disease and recognise the current pandemic threat.

Original languageEnglish
Article numbere2508
JournalReviews in Medical Virology
Volume34
Issue number1
DOIs
Publication statusPublished - 2024 Jan

Bibliographical note

Publisher Copyright:
© 2024 John Wiley & Sons Ltd.

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: A systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this